Q-omics provides the consensus-scored TMEM249 profile across patient tissues and cancer cell-line models. TMEM249 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM249 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, TMEM249 RNA expression shows 15,080 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where TMEM249 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM249 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM249 survival associations across molecular data types. TMEM249 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM249 RNA expression–survival associations across cancer types. High TMEM249 expression shows unfavorable associations in KIRC, ACC, THCA, MESO, LIHC and UVM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM249 RNA expression.
This table summarizes TMEM249 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM249. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM249 shows higher tumor expression in COAD, HNSC, BLCA, LUAD, LIHC and READ. The COAD box plot shows higher TMEM249 RNA expression in tumor versus normal tissue (log2 FC = +0.875, t-test p < 0.001).
This table shows molecular features associated with TMEM249 in patient tissues and cancer cell lines. In patient samples, TMEM249 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM249 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BONE.
